SCINAI IMMUNOTHERAPEUTICS LTD. Research and Development Expense
SCINAI IMMUNOTHERAPEUTICS LTD. (SCNI) reported Research and Development Expense of $2.37 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-01.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-04-01
- SCINAI IMMUNOTHERAPEUTICS LTD. research and development expense for the quarter ending 2023-06-30 was $1.45M, a 26.34% decline year-over-year.
- SCINAI IMMUNOTHERAPEUTICS LTD. research and development expense for the quarter ending 2023-03-31 was $2.00M, a 71.54% increase year-over-year.
- SCINAI IMMUNOTHERAPEUTICS LTD. research and development expense for the quarter ending 2022-06-30 was $1.97M.
- SCINAI IMMUNOTHERAPEUTICS LTD. research and development expense for the quarter ending 2022-03-31 was $1.16M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 12 month |
|---|---|---|---|
| 2025-12-31 | $2.37M 20-F · filed 2026-04-01 | ||
| 2025-06-30 | $1.24M 6-K · filed 2025-09-02 | ||
| 2024-12-31 | $5.53M 20-F · filed 2026-04-01 | ||
| 2024-06-30 | $2.79M 6-K · filed 2025-09-02 | ||
| 2023-12-31 | $5.21M 20-F · filed 2026-04-01 | ||
| 2023-06-30 | $1.45M 6-K/A · filed 2023-08-18 | $3.45M 6-K · filed 2024-09-09 | |
| 2023-03-31 | $2.00M 10-Q · filed 2023-05-15 | ||
| 2022-12-31 | $5.76M 20-F · filed 2025-05-07 | ||
| 2022-06-30 | $1.97M 6-K/A · filed 2023-08-18 | $3.14M 6-K/A · filed 2023-08-18 | |
| 2022-03-31 | $1.16M 10-Q · filed 2023-05-15 | ||
| 2021-12-31 | $3.25M 20-F · filed 2024-05-15 |